Sugi Predict

Sugi Predict / Compounds / SCHEMBL1059670

SCHEMBL1059670

SCHEMBL1059670

N[C@@H]1CCCN(c2cc3nc[nH]c(=O)c3c(Nc3ccc4c(c3)OCO4)n2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 6/20 0.41
▸ SYK P43405 4/20 0.41
▸ ZAP70 P43403 3/20 0.41
▸ CDK1 P06493 1/20 0.40
▸ CAMK1D Q8IU85 4/20 0.39
▸ JAK1 P23458 2/20 0.39
▸ DPP4 P27487 4/20 0.39
▸ JAK3 P52333 2/20 0.38
▸ BTK Q06187 2/20 0.38
▸ USP2 O75604 1/20 0.38
▸ LYN P07948 2/20 0.38
▸ RET P07949 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ ALK Q9UM73 1/20 0.38
▸ EGFR P00533 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1058372 0.86 SYK (0.46) JAK2SYKZAP70CAMK1DDPP4
SCHEMBL1053457 0.78 SYK (0.39) JAK2SYKZAP70CDK1CAMK1D
SCHEMBL1056394 0.76 CDK1 (0.49) JAK2SYKCDK1JAK1MEN1
SCHEMBL3427467 0.75 USP2 (0.40) DPP4JAK3BTKUSP2EGFR
SCHEMBL12932023 0.75 CAMK1D (0.39) JAK2SYKZAP70CAMK1DDPP4
SCHEMBL1058458 0.73 JAK2 (0.46) JAK2SYKZAP70JAK1JAK3
SCHEMBL1051535 0.72 SYK (0.65) JAK2SYKZAP70CDK1LYN
SCHEMBL12928849 0.71 ZAP70 (0.66) JAK2SYKZAP70JAK3BTK
SCHEMBL1048871 0.71 ZAP70 (0.66) JAK2SYKZAP70JAK3BTK
SCHEMBL1056532 0.70 SYK (0.65) JAK2SYKZAP70BTKUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354526-B2 Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors IRM LLC (BM) 2013-01-15 — — US claimed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US claimed
US-8354526-B2 Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors IRM LLC (BM) 2013-01-15 — — US disclosed
US-8354526-B2 Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors IRM LLC (BM) 2013-01-15 — — US disclosed
US-8354526-B2 Pyrido [4, 3-D] pyrimidinone derivatives as kinase inhibitors IRM LLC (BM) 2013-01-15 — — US disclosed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US disclosed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US disclosed
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2011-01-06 — — US disclosed
EP-2250169-A1 PYRIDO [4, 3-D]PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2010-11-17 — — EP disclosed
WO-2009099801-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2009-08-13 — — WO disclosed
WO-2009099801-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS IRM LLC (BM) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003790-A1 PYRIDO [4, 3-D] PYRIMIDINONE DERIVATIVES AS KINASE INHIBITORS ZAP70, FLT3, LCK JAK2 58/4885SYK 18/4885ZAP70 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.